Skip to main content
Article thumbnail
Location of Repository

Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer

By Blandine Betton, Philippe O. Gannon, Ismaël Hervé Koumakpayi, Jean-Simon Diallo, Anne-Marie Mes-Masson and Fred Saad

Abstract

Objectives: In the present study, we investigated whether the pH of IP6 could influence its anti-tumoral activity in vitro. Methods: PC-3 cells were exposed to IP6 at pH 5, pH 7, and pH 12 and we evaluated the metabolic activity (WST-1 assay), cell proliferation (cell count), cell cycle distribution (FACS), and mitochondrial depolarization (JC-1 staining) in vitro. Results: Our results demonstrated that IP6 at pH 5 and pH 12 were more potent at lowering the metabolic activity of PC-3 cells than IP6 at pH 7. Treatment with IP6 at pH 12 also caused the greatest inhibition in cellular proliferation and accumulation of PC-3 cells in sub-G1. Finally, IP6 at pH 12 lead to a reduction in phospho-AKT and phospho-PDK1 and upregulated phospho-ERK. Conclusion: Together, our data strongly suggest that the pH of IP6 effectively modulates its anti-tumoral activity and should be reported in future studies

Topics: Oncology
Publisher: Frontiers Research Foundation
OAI identifier: oai:pubmedcentral.nih.gov:3356122
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2006). An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the pc3/pc3(ar) prostatecancercelllines.Prostate 66,
    2. andSaad,F.(2008).Enhancedkilling of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.
    3. (2003). Cancer inhibition by inositolhexaphosphate(ip6)andinositol: from laboratory to clinic.
    4. (2006). Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    5. (2000). Impairment of erbb1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinomadu145cells.Carcinogenesis 21,
    6. (2004). In vivo suppression of hormonerefractory prostate cancer growth by inositol hexaphosphate: induction of insulin-likegrowthfactorbinding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res.
    7. (2011). Influence of pH on the cytotoxic activity of inositol hexakisphosphate (IP6) in prostate cancer.
    8. (1993). Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate.
    9. (1999). Inositol hexaphosphate (ip6) as an antineoplastic and lipid-lowering agent.
    10. (2010). Inositol hexaphosphate downregulates both constitutive and ligand-induced mitogenic and cell survival signaling, and causes caspase-mediated apoptotic death of human prostate carcinoma pc-3 cells.
    11. (1995). Inositol hexaphosphate inhibits growth and induces differentiation of pc-3 human prostate cancer cells.
    12. (2004). Inositol hexaphosphate inhibits growth and induces g1 arrest and apoptotic death of androgendependent human prostate carcinoma lncap cells.
    13. (2003). Inositol hexaphosphate inhibits growth, and induces g1 arrest and apoptotic death of prostate carcinoma du145 cells: modulation of cdki-cdk-cyclin and prb-related protein-e2f complexes.
    14. (2006). Inositol hexaphosphate represses telomerase activity and translocates tert from the nucleus in mouse and human prostate cancer cells via the deactivation of akt and pkcalpha.
    15. (2009). Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: Pi3k-akt pathway as potential target.
    16. (1997). Ip6: a novel anticancer agent.
    17. IP6’s activity in prostate cancer APPENDIX FIGUREA1 | pH variations of the culture media after IP6 or water treatment. PC-3 cells were plated at 200,000 cells/ml in 6-well plates in a final volume of 3ml of medium/well.The culture media consists
    18. (1999). Mitochondrial depolarization accompanies cytochrome c release during apoptosis in pc6 cells.
    19. (2009). P21/cip1 and p27/kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.
    20. (1991). Phytic acid and minerals: effect on early markers of risk for mammary and colon carcinogenesis.
    21. (1987). Phytic acid. A natural antioxidant.
    22. (2006). Protection against cancer by dietaryip6andinositol.Nutr.Cancer 55,
    23. (2005). Regulation of blood glucose by hypothalamic pyruvate metabolism.
    24. (2001). Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine.
    25. (2004). Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
    26. (1993). Specific proteolytic cleavage of poly(adpribose) polymerase: an early marker of chemotherapy-induced apoptosis.
    27. (2011). Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Received:12July2011;accepted:04October 2011; published online: 31
    28. (1996). Synthesis and iron binding studies of myo-inositol 1,2,3-trisphosphate and (±)-myo-inositol 1,2-bisphosphate, and iron binding studies of all myo-inositol tetrakisphosphates.
    29. (2000). The role of phytic acid in legumes: antinutrient or beneficial function?
    30. (2011). Volume 1 | Article 40 | 7Betton et al. IP6’s activity in prostate cancer

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.